GSK2578215A；一种有效的、高度选择性的 2-芳基甲氧基-5-取代-N-芳基苯甲酰胺 LRRK2 激酶抑制剂。
GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
机构信息
External Alliances & Development, R&D China, GlaxoSmithKline Pharmaceuticals R&D, Stevenage, UK.
出版信息
Bioorg Med Chem Lett. 2012 Sep 1;22(17):5625-9. doi: 10.1016/j.bmcl.2012.06.104. Epub 2012 Jul 7.
Abstract
Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for some forms of Parkinson's disease. Here we report the discovery and characterization of 2-arylmethyloxy-5-subtitutent-N-arylbenzamides with potent LRRK2 activities exemplified by GSK2578215A which exhibits biochemical IC(50)s of around 10 nM against both wild-type LRRK2 and the G2019S mutant. GSK2578215A exhibits exceptionally high selectivity for LRRK2 across the kinome, substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.3-1.0 μM in cells and in mouse spleen and kidney, but not in brain, following intraperitoneal injection of 100mg/kg.
摘要
富含亮氨酸重复激酶 2（LRRK2）是某些帕金森病形式的有前途的治疗靶标。在这里，我们报告了具有强效 LRRK2 活性的 2-芳基甲氧基-5-取代-N-芳基苯甲酰胺的发现和表征，其中 GSK2578215A 是一个很好的例子，其对野生型 LRRK2 和 G2019S 突变体的生化 IC50 约为 10 nM。GSK2578215A 在激酶组中对 LRRK2 具有极高的选择性，在腹腔注射 100mg/kg 后，在细胞和小鼠脾脏和肾脏中，浓度为 0.3-1.0 μM 时，可显著抑制野生型 LRRK2 和 G2019S 突变体的 Ser910 和 Ser935 磷酸化，但在大脑中没有。
相似文献
1
GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
Bioorg Med Chem Lett. 2012 Sep 1;22(17):5625-9. doi: 10.1016/j.bmcl.2012.06.104. Epub 2012 Jul 7.
2
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. doi: 10.1016/j.bmcl.2012.01.084. Epub 2012 Jan 28.
3
Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
J Med Chem. 2015 Jan 8;58(1):419-32. doi: 10.1021/jm5014055. Epub 2014 Nov 17.
4
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6.
5
Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
Biochemistry. 2013 Mar 12;52(10):1725-36. doi: 10.1021/bi3012077. Epub 2013 Mar 1.
6
Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
Future Med Chem. 2012 Sep;4(13):1701-13. doi: 10.4155/fmc.12.110.
7
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Biochem J. 2010 Sep 15;430(3):393-404. doi: 10.1042/BJ20100483.
8
Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
Bioorg Med Chem Lett. 2013 Apr 1;23(7):1974-7. doi: 10.1016/j.bmcl.2013.02.041. Epub 2013 Feb 15.
9
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Biochem J. 2010 Sep 15;430(3):405-13. doi: 10.1042/BJ20100784.
10
Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Expert Opin Ther Pat. 2012 Dec;22(12):1415-26. doi: 10.1517/13543776.2012.729041. Epub 2012 Nov 6.
引用本文的文献
1
LRRK2 kinase modulates glucose-stimulated insulin secretion via RAB8 phosphorylation and ciliogenesis.
Cell Mol Life Sci. 2025 Jul 17;82(1):276. doi: 10.1007/s00018-025-05810-w.
2
Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease.
Neurol Sci. 2025 Apr;46(4):1509-1524. doi: 10.1007/s10072-024-07970-2. Epub 2025 Jan 6.
3
The design and development of LRRK2 inhibitors as novel therapeutics for Parkinson's disease.
Future Med Chem. 2025 Jan;17(2):221-236. doi: 10.1080/17568919.2024.2444875. Epub 2024 Dec 24.
4
Microglial Sp1 induced LRRK2 upregulation in response to manganese exposure, and 17β-estradiol afforded protection against this manganese toxicity.
Neurotoxicology. 2024 Jul;103:105-114. doi: 10.1016/j.neuro.2024.05.007. Epub 2024 Jun 8.
5
Molecular mechanisms defining penetrance of -associated Parkinson's disease.
Med Genet. 2022 Aug 12;34(2):103-116. doi: 10.1515/medgen-2022-2127. eCollection 2022 Jun.
6
Parkinson's disease kinase LRRK2 coordinates a cell-intrinsic itaconate-dependent defence pathway against intracellular Salmonella.
Nat Microbiol. 2023 Oct;8(10):1880-1895. doi: 10.1038/s41564-023-01459-y. Epub 2023 Aug 28.
7
Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy.
Mol Ther. 2023 Oct 4;31(10):2929-2947. doi: 10.1016/j.ymthe.2023.07.021. Epub 2023 Jul 28.
8
Perspective on the current state of the LRRK2 field.
NPJ Parkinsons Dis. 2023 Jul 1;9(1):104. doi: 10.1038/s41531-023-00544-7.
9
LRRK2 Kinase Inhibition Attenuates Astrocytic Activation in Response to Amyloid β Fibrils.
Biomolecules. 2023 Feb 6;13(2):307. doi: 10.3390/biom13020307.
10
Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.
Genes (Basel). 2022 Aug 11;13(8):1426. doi: 10.3390/genes13081426.
本文引用的文献
1
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. doi: 10.1016/j.bmcl.2012.01.084. Epub 2012 Jan 28.
2
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.
ACS Chem Biol. 2011 Oct 21;6(10):1021-8. doi: 10.1021/cb2002413. Epub 2011 Aug 10.
3
Role of LRRK2 kinase dysfunction in Parkinson disease.
Expert Rev Mol Med. 2011 Jun 13;13:e20. doi: 10.1017/S146239941100192X.
4
On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
Neurosignals. 2011;19(1):1-15. doi: 10.1159/000324488. Epub 2011 Mar 23.
5
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6.
6
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Biochem J. 2010 Sep 15;430(3):405-13. doi: 10.1042/BJ20100784.
7
LRRK2 and Parkinson disease.
Arch Neurol. 2010 May;67(5):542-7. doi: 10.1001/archneurol.2010.79.
8
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
Biochem J. 2009 Oct 23;424(1):47-60. doi: 10.1042/BJ20091035.
9
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
ASN Neuro. 2009 Apr 14;1(1):e00002. doi: 10.1042/AN20090007.
10
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
J Neurosci Res. 2009 May 1;87(6):1283-95. doi: 10.1002/jnr.21949.
Zotero 插件